FDA Approves Medtronic’s Valiant Captivia Thoracic Stent Graft System for Aortic Dissections


February 3, 2014
Medtronic Valiant Captivia Thoracic Stent Graft System Aneurism Repair AAA TAA

Medtronic Inc.’s Valiant Captivia Thoracic Stent Graft System treats type B aortic dissections. Indicated for a variety of thoracic aortic lesions, the Valiant Captivia System features a proximal tip-capture mechanism, enabling controlled deployment and accurate placement of the stent graft. The Valiant stent graft maintains apposition to the vessel wall regardless of angulation or oversizing.  Medtronic expanded the size matrix of the Valiant Captivia Thoracic Stent Graft System with 11 proximal FreeFlo tapered pieces. The pieces all taper by 4 mm along their approximately 150 mm length, and have proximal diameters ranging 26 mm to 46 mm. These additional system components received FDA approval, CE marking and Health Canada approval in January 2014. In Europe, they are approved for use in treating thoracic aortic aneurysms, transections and dissections; in the United States, for thoracic aortic aneurysms and transections; and in Canada, for thoracic aortic aneurysms. FDA approved the Valiant Captivia System in January 2014.  For more information: www.medtronic.com

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.